- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415552
Implementation of Online Mindfulness-Based Stress Reduction Tailored for People With Multiple Sclerosis
This project aims to implement and investigate a mindfulness-based stress reduction (MBSR) in people with multiple sclerosis (PwMS). The main objective is to implement MBSR intervention for PwMS in a major tertiary care clinic for PwMS. We will iteratively refine the intervention as required based on stakeholder feedback and any other emergent contextual findings.
Participants will be asked to take part in an 8-week MBSR course and report changes in anxiety, depression, quality of life, emotional regulation, self-compassion, mindfulness, and health services use.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Simpson
- Phone Number: 40047 416-360-4000
- Email: Robert.Simpson@unityhealth.to
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >18 years </= 60 years
- Diagnosis of MS or related condition (Clinically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorder, Chronic Inflammatory Demyelinating Neuropathy)
- Able to understand spoken and written English
- Willing to take part in an MBSR course
Exclusion Criteria:
- Cognitive impairment (<26 on the Montreal Cognitive Assessment)
- Severe active mental health impairment (psychosis, suicidality)
- Medical instability (terminal/life threatening inter-current illness)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Mindfulness-Based Stress Reduction
8-week Mindfulness-Based Stress Reduction course
|
Eight iterations of the MBSR course will be delivered, over a total period of 24 months.
Each iteration will take place over 8 weeks.
Courses would consist of 8 weekly sessions, led by certified mindfulness instructors.
Sessions will include core meditation practices, psychoeducation, and home practices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment
Time Frame: 24 months
|
The investigators will measure the number of participants eligible for and recruited to the study.
|
24 months
|
Retention
Time Frame: 24 months
|
The investigators will measure the percentage of participants who complete outcome data.
|
24 months
|
Adherence
Time Frame: 24 months
|
The investigators will measure the number of participants who completed the mindfulness-based stress reduction course.
|
24 months
|
Follow-up rates
Time Frame: 24 months
|
The investigators will measure the percentage of participants who complete outcome measures pre-intervention, post-intervention, and at 3 months post-intervention.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29)
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Multiple Sclerosis Impact Scale.
Items on the scale have a Likert scale from 1-5, with a range of 0-100 total and higher scores indicating greater disability.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Quality of Life using the EuroQol (EQ-5D-5L)
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the EQ-5D-5L.
The total score ranges from 1-100, with higher values indicating better perceived health.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Anxiety
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Hospital Anxiety and Depression Scale.
The total score ranges from 0-21, with higher values representing increased anxiety symptoms.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Depression
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Hospital Anxiety and Depression Scale.
The total score ranges from 0-21, with higher values representing increased anxiety symptoms.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Health services use
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Client Services Receipt Inventory.
This instrument is used to collect information on the use of health services.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Emotion regulation
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Difficulties in Emotion Regulation Scale - Short Form.
Answers are assessed using a 5-point Likert scale.
Higher values indicate greater difficulties in emotion regulation.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Self-compassion
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Self-Compassion Scale - Short Form.
The total score ranges from a 1-5 Likert scale, with higher scores representing high self-compassion.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Mindfulness
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Five-facet Mindfulness Questionnaire.
Answers are assessed using a 5-point Likert scale.
Higher scores in each facet indicate higher levels of mindfulness.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Climate
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Group Climate Questionnaire-Engage Scale.
Each item response is measured on a Likert scale from 0-6, with total subscale scores reflecting the average of responses.
Higher scores indicate higher group engagement.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Therapeutic alliance
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Working Alliance Inventory.
Each item is measured on a 7-point Likert scale, with a range of 36-252 total.
Higher scores indicates stronger alliance.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Sleep
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Insomnia Severity Index.
The total score ranges from 0-28, with higher scores indicating worse insomnia.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Pain Effects
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Pain Effects Scale.
The total score ranges from 6-30, with higher scores indicating greater impact of pain on behavior and mood.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Fatigue
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Modified Fatigue Impact Scale.
The total score ranges from 0-84, with higher scores indicating a greater impact of fatigue.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Cognitive function
Time Frame: Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Measured using the Symbol Digits Modalities Test.
The total score ranges from 0-110, with higher scores indicating better cognitive functioning.
|
Measured at baseline, 8-week follow-up, and 3-month follow-up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mindfulness for PwMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Mindfulness-Based Stress Reduction
-
Duke UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Inflammation | Stress, Psychological | SleepUnited States
-
University of California, San FranciscoCompletedDementia | Frontotemporal Dementia | Frontotemporal Lobar Degeneration | Caregiver Stress Syndrome | Caregiver Burnout | Dementia Frontal | Mindfulness Based Stress ReductionUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Oregon Health and Science UniversityPortland VA Medical CenterCompleted
-
Chang Gung Memorial HospitalRecruitingLate Life DepressionTaiwan
-
Schneider Children's Medical Center, IsraelCompletedInflammatory Bowel DiseasesIsrael
-
Clemson UniversityUniversity of California, Los Angeles; Prisma Health-UpstateCompletedQuality of Life | Diabetes | Stress | Health Behavior | Pre-DiabetesUnited States
-
University of AarhusVU University of AmsterdamUnknown
-
Johns Hopkins UniversityCompleted
-
Spaulding Rehabilitation HospitalCompletedStress | Brain Injury | Traumatic Brain InjuryUnited States